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Aims: Hypnotic zolpidem is a positive allostericmodulator of γ-aminobutyric acid (GABA) action, with preferen-
tial although not exclusive binding for α1 subunit-containing GABAA receptors. The pharmacological profile of
this drug is different from that of classical benzodiazepines, although it acts through benzodiazepine binding
sites at GABAA receptors. The aim of this study was to further explore the molecular mechanisms of
GABAA receptor induction by zolpidem.
Main methods: In the present study, we explored the effects of two-day zolpidem (10 μM) treatment on
GABAA receptors on the membranes of rat cerebellar granule cells (CGCs) using [3H]flunitrazepam binding
and semi-quantitative PCR analysis.
Key findings: Two-day zolpidem treatment of CGCs did not significantly affect the maximum number
(Bmax) of [3H]flunitrazepam binding sites or the expression of α1 subunit mRNA. However, as shown by
decreased GABA [3H]flunitrazepam binding, two-day exposure of CGCs to zolpidem caused functional
uncoupling of GABA and benzodiazepine binding sites at GABAA receptor complexes.
Significance: If functional uncoupling of GABA and benzodiazepine binding sites at GABAA receptors is the
mechanism responsible for the development of tolerance following long-term administration of classical
benzodiazepines, chronic zolpidem treatment may induce tolerance.© 2012 Elsevier Inc. All rights reserved.Introduction
Gamma-aminobutyric acid type A (GABAA) receptors are pent-
americ complexes of subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π) that form
central anion channels that mediate inhibition in the central nervous
system (Korpi et al., 2002). Theα1 subunit receptors are themost abun-
dant subtype of synaptic GABAA receptors expressed in the brain (Olsen
and Sieghart, 2008). GABAA receptors can be modulated by a variety of
pharmacologically and clinically relevant drugs, such as benzodiazepines,
barbiturates, neuroactive steroids, anesthetics, etc.
Zolpidem, an imidazopyridine with a chemical structure different
from that of classical benzodiazepines, exhibits high selectivity for α1
subunit-containing GABAA receptors (Depoortere et al., 1986; Olsen
and Sieghart, 2008). Using a knock-in approach, Crestani et al.
(2000) confirmed the preferential affinity of zolpidem for the α1 sub-
type of GABAA receptors, and Cope et al. (2004) demonstrated the
contribution of the γ2 subunit to its action in vivo. In addition to its
pronounced sedative properties and mild anxiolytic and myorelaxant
effects (Depoortere et al., 1986; Sanger et al., 1996), several publishedOB 180, 10000 Zagreb, Croatia.
rights reserved.papers have suggested that zolpidem might have better anticonvul-
sant activity than previously thought (Crestani et al., 2000; Peričić
et al., 2008; Vlainić and Peričić, 2010).
Long-term administration of positive allosteric modulators of
GABAA receptors, such as benzodiazepines, often results in the devel-
opment of tolerance and dependence, phenomena accompanied by
different adaptive changes in the GABAergic system. These changes
mainly lead to altered receptor expression and/or function. While
the observed changes in receptor expression have been inconsistent
(Wafford, 2005), many researchers working either on animals (Gallager
et al., 1984), neuronal cultures (Roca et al., 1990; Friedman et al., 1996)
or recombinant receptors (Primus et al., 1996; Ali and Olsen, 2001;
Peričić et al., 2007; Švob Štrac et al., 2008; Vlainić et al., 2010) have
found functional uncoupling of allosteric linkages between GABA and
benzodiazepine binding sites, characterized by decreased ability of
benzodiazepines to potentiate the action of GABA as well as by de-
creased ability of GABA to enhance benzodiazepine binding (Gallager
et al., 1984). It has been suggested that this phenomenonmay be related
to the development of tolerance to benzodiazepine action. However, de-
spite many studies on this topic, the molecular mechanisms involved in
the development of tolerance and dependence following long-term treat-
ment with benzodiazepines are still unclear (Bateson, 2002; Wafford,
2005; Uusi-Oukari and Korpi, 2010).
The first studies in rodents suggested that, unlike benzodiazepines
that bind non-selectively, repeated treatment with zolpidem does not
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our previous study demonstrated development of anticonvulsant
and sedative tolerance after repeated (twice daily for 10 days)
zolpidem treatment in mice, similar to that produced by prolonged
diazepam treatment (Vlainić and Peričić, 2009).Moreover, the re-
sults of another study (Vlainić et al., 2010) suggested that two-
day zolpidem treatment of human embryonic kidney (HEK) 293
cells stably expressing recombinant α1β2γ2s GABAA receptors
up-regulated the number of [3H]flunitrazepam, [3H]muscimol and
[3H]TBOB (t-butylbicycloorthobenzoate, a radioligand for the channel
site) binding sites and impairs allosteric interactions between GABA
and benzodiazepine binding sites. To elucidate further the molecular
mechanisms of zolpidem treatment, we applied the same two-day pro-
tocol on cultured rat cerebellar granule cells (CGCs) in the present
study.
CGCs constitute the majority of neurons in the cerebellum and ex-
press 14 different subunits (α1-6, β1-3, γ1-3 and δ) of GABAA recep-
tors (Bovolin et al., 1992), but with a different expression patterns
than that observed in the cerebellum of adult rats (Laurie et al.,
1992). Radioligand binding studies and semi-quantitative RT-PCR
were used to explore the effects of zolpidem treatment on the expres-




The chemicals that were used in the studywere purchased from a va-
riety of suppliers. Culture medium, antibiotics and fetal bovine serum
were supplied from Invitrogen/Gibco (Grand Island, NY, USA). Trypsin,
deoxyribonuclease (DNase), poly-L-lysine, cytosine arabinofuranoside,
GABA and diazepam were purchased from Sigma. Zolpidem
tartrate (N,N,6-trimethyl-2-(4-methylphenyl)-imidazo-(1,2-a)pyridine-
3-acetamide)was generously donated by itsmanufacturer (Pliva, Zagreb,
Croatia). [3H]Flunitrazepam (specific activity 87 Ci/mmol) was pur-
chased from Amersham Biosciences UK Ltd.
Cell culture
Primary cultures of granule cells were isolated from the cerebel-
lum of rats on postnatal day 8 according to the procedure adapted
from Oberdoerster and Rabin (1999). Briefly, the cerebella from de-
capitated rats were dissected out and minced, and then, the tissue
was digested at 37 °C for 15 min with 0.125% trypsin and 0.2%
DNase. The trypsin was inactivated by the addition of Dulbecco's
Modified Eagle's Medium (DMEM) containing 10% fetal bovine
serum. The cell pellet was centrifuged at 1000×g for 5 min, re-
suspended in DMEM, filtered through a 100-μm nylon mesh and cen-
trifuged again. The remaining cell pellet was re-suspended in DMEM.
The cells were plated (2×106 cells per cm2) in a dish that was coated
with poly-L-lysine (10 μg/ml, Mr=70,000–150,000) and maintained
at 37 °C in a 5% CO2 atmosphere. The cells were cultured in DMEM
supplemented with 10% heat-inactivated fetal bovine serum, 2 mM
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 25 mM KCl
(a high concentration of K+ is necessary to induce membrane depo-
larization to maintain viable granule cells in culture) and 50 mM
glucose. Anti-mitotic cytosine arabinofuranoside (AraC; final concen-
tration 10 μM) was added to cultures on day 1 after isolation to inhib-
it proliferation of non-neuronal cells. The culture medium was
replaced every day with fresh medium. The cells were maintained in
culture for a total of 8 days, and two-day treatmentwith zolpidem (dis-
solved in distilled water and diluted in culture medium to a final con-
centration of 10 μM) was initiated accordingly.
The cells were used in experiments following culturing in vitro for
8 days to allow cell maturation and stabilization of adult channelconductance patterns. At that time, cerebellar cultures contained
more than 95% granule cells and less than 5% glia cells. In addition,
the granule cells express functional GABAA receptors (Bovolin et al.,
1992) with a subunit composition similar to that of the cerebellum
during postnatal development, but with a different pattern than
that for the cerebellum of adult rats in which only several α subunits
are expressed (Laurie et al., 1992).
All experimental procedures in the present study were approved
by the Ruđer Bošković Institute's Animal Research Committee and
were performed in accordance with the Principles of National Insti-
tute for the Care and Use of Laboratory Animals (NIH publication
No. 86–23, revised 1996) and the principles presented in the “Guide-
lines for the Use of Animals in Neuroscience Research” by the Society
for Neuroscience. All efforts were made to minimize animal suffering
and to reduce the number of animals used.
[3H]flunitrazepam binding assay
Membranes from cultured CGCs were prepared with modifica-
tions of the method described previously (Peričić et al., 2004). The
cells were washed with phosphate-buffer saline (PBS), scraped from
flasks into ice-cold PBS and centrifuged at 12,000×g for 12 min. The
cell pellet was homogenized in 50 mM Tris-citrate buffer, pH 7.4,
using a teflon pestle and a glass homogenizer and then centrifuged
at 200,000×g for 20 min. The same procedure was repeated two
more times (re-suspension/centrifugation). Finally, the pellet was
re-suspended and stored in aliquots at −20 °C. The suspension of
the cell membranes was centrifuged on the day of [3H]flunitrazepam
binding assay once more at 200,000×g for 20 min.
In vitro benzodiazepinebindingwas assayswere performedonmem-
brane preparations, as previously described, using [3H]flunitrazepamas a
radioligand (Peričić et al., 2005). Aliquots of cell membrane preparations
were incubated in 50 mMTris-citrate buffer supplementedwith 150 mM
NaCl at 4 °C for 90 min with a fixed concentration (1 nM) of [3H]
flunitrazepam. In stimulation studies (GABA-shift), GABA (final concen-
tration 100 μM) was added and incubated with [3H]flunitrazepam.
Non-specific binding was determined by [3H]flunitrazepam bound
to the cell membranes in the presence of 100 μM diazepam and rep-
resented less than 20% of total binding. The total assay volume of all
binding studies was 0.5 ml. After rapid vacuum filtration, filters
(Whatman GF/C) were dried overnight and then soaked in a liquid
scintillation cocktail. Bound radioactivity was quantified by liquid
scintillation counting on a β-scintillation counter (Perkin Elmer,
Wallace 1409DSA).
Protein concentration assays
Membrane protein concentrations were determined in 10 μL of
membrane suspension using bovine serum albumin as a standard.
Semi-quantitative RT-PCR
Total cellular RNA was extracted using a High Pure RNA Isolation
Kit (Roche) and quantified at 260 nm using a spectrophotometer. Re-
verse transcription and semi-quantitative PCR were performed in a
PerkinElmer 9600 thermocycler, as previously described (Jazvinšćak
Jembrek et al., 2008). Together with random hexadeoxynucleotide
primers (2.5 μM), total RNA (1 μg) was denatured at 65 °C for 5 min,
and the first strand of cDNA was synthesized by adding the following
reagents: reverse transcription buffer (Invitrogen), 0.5 mM dNTPs
(Roche), 40 U of RNase-inhibitor (Roche) and 200 U of SuperScript
II reverse transcriptase (Invitrogen). For DNA synthesis, after primer
annealing (25 °C, 10 min), the reaction mixture was incubated at
42 °C for 50 min and then heated (70 °C, 15 min) for enzyme inacti-
vation. Each RT reaction had two negative controls: the sample with-
out SuperScript II reverse transcriptase and the sample without the
Fig. 1. The effect of two-day zolpidem treatment on the expression of [3H]flunitrazepam
binding sites onmembranes obtained fromCGCs. The results are expressed as themean±
SEM (n=3).
Fig. 2. The effect of two-day zolpidem treatment on the expression of GABAA receptor
α1 subunit mRNA (A) Representative agarose gel electrophoresis; (B) Results of RT-
PCR analysis. Abbreviations: size marker (M), control cells (C) zolpidem-treated cells
(Z). Data are expressed as the means±SEM from six independent RT-PCR analyses
(with PCR performed in triplicate) after three separate preparations of total RNA.
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sion of the housekeeping gene β-actin was used as an internal stan-
dard. The resulting cDNA (1:5 dilution) was amplified by PCR with
1.25 U of Taq DNA polymerase (Promega) in 20 μL of standard buffer
containing 0.2 μM of each sense and antisense primers (Invitrogen),
1.5 mM MgCl2 and 200 μM of dNTP mix. PCR primers used in this
study were as follows: β-actin, TCA CCA ACT GGG ACG ACA TG and
TTC GTG GAT GCC ACA GGA CT; GABAA receptor α1 subunit, AGC
TAT ACC CCT AAC TTA GCC AGG and AGA AAG CGA TTC TCA GTG
GAG AGG. Cycle parameters included an initial denaturation step
(95 °C, 5 min), followed by denaturation (95 °C, 30 s), annealing
(60 °C, 30 s) and extension (72 °C, 1 min). Preliminary experiments
were performed with each set of primers to assess linearity of PCR
product amplification with respect to cycle number. The PCR products
of both the α1 subunit and β-actin gene were measured during the
log phase of the reaction (35 cycles). Samples of the reaction products
were separated by electrophoresis on 1.5% agarose gels and stained
with ethidium bromide. Maximal optical density was obtained with
the Image Master VDS software (Pharmacia). The expression of α1
subunit mRNAwas normalized to β-actin mRNA expression and com-
pared between the control and zolpidem-treated groups.
Data analysis
The analysis of binding data for [3H]flunitrazepam binding was
performed using a method for calculating receptor number (Bmax)
from competitive binding data (DeBlasi et al., 1989) as follows:
B0 ¼ dpmTOTAL−dpmNONSPECIFIC=c 2220mg protein
Bmax ¼ B0  IC50=L
where dpm is the disintegrations per minute, c is the concentration of
radioactive ligand, 2220 is the number of disintegrations of 1 nCi per
minute, IC50 (nM) is the affinity of drug for receptor and L (nM) is the
concentration of radioactive ligand in the assay. These equations are
based on several assumptions: labeled and unlabeled ligand have
identical affinities for the receptor, only one class of binding site ex-
ists, there is no cooperation between binding sites and only a small
fraction of the total ligand is bound to receptors.
The percentage of change in [3H]flunitrazepambinding produced by
the presence of GABAwas defined as (specific binding in the presence of
GABA/specific binding in the absence of GABA)×100.
The results are presented as the means±SEM of at least three in-
dependent experiments. The means±SEM for maximum enhance-
ment (Emax) of [3H]flunitrazepam binding were determined from
several individual experiments performed in duplicate.
Statistical analyses of the results were conducted by Student's
t-test. P-values less than 0.05 were considered significant.Results
The effect of two-day zolpidem treatment on [3H]flunitrazepam binding
to membranes isolated from cultured CGGs
Cultured rat CGCs were treated for two days with 10 μM zolpidem.
Cell membranes were prepared as described in the Materials and
methods and incubated in the presence of 1 nM [3H]flunitrazepam.
The maximum number (Bmax) of [3H]flunitrazepam binding sites
were calculated using the formula for calculating receptor number
from binding data (DeBlasi et al., 1989). The Bmax values were 74.62±
9.67 fmol/mg protein in the control group and 75.88±3.38 fmol/mg
protein in the zolpidem-treated group (n=3). As shown in Fig. 1, there
was no significant difference between the maximum number (Bmax) of
benzodiazepine binding sites on the membranes of cells obtained from
control and zolpidem-treated cells.
The effect of two-day zolpidem treatment on GABAA receptor expression
Isolated rat CGCs were treated for two days with 10 μM zolpidem,
and the level of GABAA receptorα1 subunit mRNAwas determined by
semi-quantitative RT-PCR analysis. The maximal optical density of the
α1 subunit band was normalized to the expression of the housekeep-
ing gene β-actin. Incubation of CGCs in the presence of zolpidem had
no significant effect on the abundance of GABAA receptor α1 subunit
mRNA relative to control cultures (Fig. 2).
The effect of two-day zolpidem treatment on allosteric coupling between
GABA and benzodiazepine binding sites at GABAA receptor complexes
The effect of zolpidem treatment on GABA potentiation of [3H]
flunitrazepam binding as a measure of degree of allosteric linkage be-
tween GABA and benzodiazepine binding sites at GABAA receptor
complexes was studied with membranes of cerebellar granule neu-
rons incubated for two days in the presence of 10 μM zolpidem. The
GABA-shift assay was performed in the presence of 100 μM GABA
Fig. 3. The effect of two-day zolpidem treatment on GABA potentiation of [3H]
flunitrazepam binding to membranes from rat CGCs. Data are expressed as the percent-
ages of basal values. The bars are means±SEM (n=5). *Pb0.003 vs. control (Student's
t-test).
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[3H]flunitrazepam binding produced by GABA in the control group
was 104.50±6.44%, indicating that theGABAbinding sitewas function-
ally coupled to the benzodiazepine binding site. In the zolpidem-treated
group, the Emax values were significantly lower (61.66±7.95%). As
shown in Fig. 3, the results obtained indicated that two-day zolpidem
treatment decreased the level of allosteric coupling between GABA and
benzodiazepine binding sites at GABAA receptor complexes (Pb0.003).
Discussion
Zolpidem is a positive allosteric modulator of GABA action with se-
lectivity for α1 subunit-containing GABAA receptors. It was previously
thought that zolpidem causes fewer side effects and a lower degree of
tolerance during long-term administration than benzodiazepines
(Perrault et al., 1992; Sanger et al., 1996). However, mice treated re-
peatedly with zolpidem, similar to those treated repeatedly with diaze-
pam, have been found to develop tolerance to its sedative and
anticonvulsant effects (Vlainić and Peričić, 2009). Similar results were
obtained in rats (Auta et al., 2008). In addition, the World Health Or-
ganization reports that the frequency of zolpidem abuse and depen-
dence is similar to that of benzodiazepines. Moreover, it has been
emphasized that there are not enough studies on the use of high doses
of zolpidem.
To extend our previous work suggesting that two-day zolpidem
treatment up-regulates the expression of α1β2γ2s GABAA recep-
tors in HEK 293 cells (Vlainić et al., 2010), we investigated the ef-
fect of two-day zolpidem (10 μM) treatment on GABAA receptors
expressed in primary rat CGCs. The results demonstrated that
treatment with zolpidem failed to change the maximum number
(Bmax) of [3H]flunitrazepam-labeled benzodiazepine binding sites
or the level of α1 subunit GABAA receptor mRNA. The number of
benzodiazepine binding sites found was in agreement with the
number of [3H]flunitrazepam binding sites observed by Zhu et al.
(1995). In their study on primary culture of rat CGCs, the maximum
number of benzodiazepine binding sites was 59±7 fmol/mg protein
and 100±7 fmol/mg protein in the presence of low and high K+,
respectively.
Although down-regulation of GABAA receptor number is consid-
ered a potential mechanism for the development of tolerance in re-
sponse to prolonged benzodiazepine treatment, a decrease in the
number of benzodiazepine binding sites has been observed in only a
few studies (for review see Bateson, 2002). As in the present study,
most radioligand binding studies have reported no changes in the
number of benzodiazepine binding sites following prolonged treat-
ment with positive allosteric modulators of the GABAA receptor
(Bateson, 2002; Uusi-Oukari and Korpi, 2010). In accordance with
our results, Follesa et al. (2002) observed no changes in the levels ofGABAA receptor mRNA (α1, α4, γ2L, γ2S) following treatment of
CGCs with 10 μM zolpidem for 5 days. In contrast, Holt et al. (1997),
who studied the effects of zolpidem treatment in rats, reported that
the effects on GABAA receptor gene expression in the cortex
depended on the exposure time: the effect obtained after 7 days (in-
creased level of α4 mRNA) markedly differed from that observed
after 14 days (decreased level of α1 mRNA). Decreased expression
of α1 GABAA receptor subunit mRNA was also observed in the pre-
frontal cortex after treatment of rats with zolpidem for 14 days
(Auta et al., 2008).
The results of the present study show that two-day zolpidem treat-
ment did not change themaximumnumber of [3H]flunitrazepam-labeled
benzodiazepine binding sites; these data differ from our previous that
demonstrated zolpidem-mediated up-regulation of [3H]flunitrazepam,
[3H]muscimol and [3H]TBOB binding sites on recombinant α1β2γ2s
GABAA receptors in HEK 293 cells (Vlainić et al., 2010). There are several
possible reasons for this discrepancy. For example, while in the previous
study we investigated the effect of drug on one subtype of GABAA recep-
tors (α1 subunit-containing), the population of GABAA receptors in CGCs
is heterogeneous (Bovolin et al., 1992).
[3H]Flunitrazepam is not a subtype-selective ligand because with
benzodiazepine sensitive γ2 subunit-containing receptors, beside
α1, α2, α3 and α5 subunit-containing GABAA receptors are labeled.
Thus, it is possible that in our previous study, zolpidem-mediated
up-regulation of α1 subtype GABAA receptors was masked by simul-
taneous up-regulation of GABAA receptors containing other alpha
subunit isoforms.
Bovolin et al. (1992) reported that the alpha subunit family mem-
bers α1, α5 and α6 are expressed in granule cells. While the expres-
sion of the α5 subunit mRNA was found to be several times lower
than that of the α1 subunit, the levels of α4 and especially α2 and
α3 mRNAs are very low. Additionally, GABAA receptors containing
α4 and α6 subunits are benzodiazepine- and zolpidem-insensitive
(Sieghart, 1995). Moreover, unlike classical benzodiazepines that
are non-selective, zolpidem has a very high affinity for receptors
containing the α1 subunit, intermediate affinity for receptors that
contain α2 or α3, and very low affinity for α5 subunit-containing
GABAA receptors (Arbilla et al., 1985; Depoortere et al., 1986;
Sanna et al., 2002; Ci et al., 2007; Korpi et al., 2002). Thus, it does
not seem likely that zolpidem-mediated up-regulation of the α1 sub-
type of GABAA receptors could compensate by simultaneously caus-
ing down-regulation of GABAA receptors containing other alpha
subunit isoforms.
The γ2 subunit together with the α subunit is essential for benzo-
diazepine binding and pharmacology (Pritchett et al., 1989; Buhr and
Sigel, 1997). Cope et al. (2004) demonstrated in vivo that the γ2 sub-
unit is important for the action of zolpidemaswell. Therefore, altered ex-
pression of this subunit would affect the binding of [3H]flunitrazepam to
its binding sites located at the interface of an α and a γ2 subunit
(Sieghart, 1995; Buhr and Sigel, 1997). Nevertheless, it has been reported
that long-term (7 days) treatment of rats, as well as cultured CGCs
(5 days) with zolpidem, had no effect on γ2 mRNA expression (Holt
et al., 1997; Follesa et al., 2002).
Thus, as in the present study neither the level of α1 subunit mRNA
nor the number of [3H]flunitrazepam-labeled benzodiazepine bind-
ing sites changed following two-day zolpidem treatment, we postu-
late that the expression of the α1 and γ2 subunits was not changed
either. This hypothesis is supported in part by the study of Uusi-Oukari
et al. (2000). These authors observed down-regulation of α1 mRNA
levels in forebrain accompanied with similar down-regulation of α1
polypeptide,which confirmed their hypothesis that there is a tight corre-
lation between α1 mRNA and polypeptide levels.
Thus, we suggest that differences between the results obtained in
this study on CGCs and those observed previously on the recombinant
α1β2γ2s GABAA receptors might be explained by differences in the
experimental models used. Although the HEK 293 cell line, as a
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GABAA receptor subtypes, the regulation of transfected genes may
not be the same as in the cultured CGCs that contain a mixture of en-
dogenous genes encoding different GABAA receptor subunits (Bovolin
et al., 1992). Additionally, although HEK 293 cells express many pro-
teins typically found in neurons (Shaw et al., 2002), the expression
profile in these cells might still be different due to a lack of a normal
neuronal environment, the absence of synapses, the absence of acces-
sory proteins or proteins affecting trafficking of receptors, etc. (Birnir
and Korpi, 2007).
It has been suggested that the functional uncoupling of GABA and
benzodiazepine binding sites, characterized by a decreased ability of
benzodiazepines to potentiate the action of GABA as well as by a de-
crease in the ability of GABA to potentiate benzodiazepine binding to
GABAA receptors, plays a role in the development of tolerance and de-
pendence to benzodiazepine-like drugs (Gallager et al., 1984). The re-
sults obtained in the present study demonstrate that the functional
interactions between GABA and benzodiazepine binding sites at
GABAA receptors were diminished in the zolpidem-treated group by
approximately 40% (Fig. 3). Although uncoupling of benzodiazepine
and GABA binding sites can be caused by drugs that inhibit protein ki-
nase A (PKA), Ali and Olsen (2001) demonstrated that direct phos-
phorylation of the GABAA receptor is not involved in the processes
of coupling and uncoupling, as mutation of the PKA phosphorylation
site did not abolish the effect of chronic benzodiazepine treatment.
They suggested that chronic benzodiazepine exposure induces internal-
ization of surface GABAA receptors into intracellular compartments,
where benzodiazepine binding can occur, but its potentiation by
GABA is impaired. However, as previously discussed, following chronic
diazepam treatment, almost all GABA and benzodiazepine binding sites
are expressed on the cell surface, suggesting that chronic exposure to
diazepam does not result in internalization of benzodiazepine binding
sites (Primus et al., 1996; Peričić et al., 2007). Nevertheless, our results
showing that two-day zolpidem treatment produced uncoupling of
GABAA receptors are in accordance with previous reports showing
uncoupling of native (Gallager et al., 1984; Hu and Ticku, 1994;
Costa and Guidotti, 1996; Brown et al., 1998) and recombinant
GABAA receptors following chronic treatment with classical benzodi-
azepines (Klein et al., 1994, 1995; Primus et al., 1996; Ali and Olsen,
2001; Švob Štrac et al., 2008) as well as zolpidem (Vlainić et al.,
2010).
The observed decreased allosteric linkage between GABA and ben-
zodiazepine binding sites could reflect conformational changes at the
binding sites of GABAA receptor complexes induced by zolpidem at
the benzodiazepine binding site. Morlock and Czajkowski (2011)
speculated that positioning of the drug at the benzodiazepine binding
site and/or positioning of nearby residues induces different down-
stream allosteric rearrangements. Thus, it remains to be determined
whether similar changes are involved in the observed zolpidem-
mediated decreased ability of GABA to potentiate binding of benzodi-
azepine binding site ligands.
Several groups of authors (Hu and Ticku, 1994; Costa and Guidotti,
1996; Brown et al., 1998) have proposed that the changes in allosteric
coupling of GABAA receptor binding sites could be the result of modifi-
cation from benzodiazepine-sensitive to benzodiazepine-insensitive
receptor subtypes and/or changes in receptor function. However, func-
tional uncoupling of GABA and benzodiazepine binding sites following
prolonged treatment with benzodiazepines (Klein et al., 1994, 1995;
Primus et al., 1996; Peričić et al., 2007; Švob Štrac et al., 2008) or
zolpidem (Vlainić et al., 2010) was observed also with recombinant
GABAA receptorswith a defined subunit composition. Therefore, we hy-
pothesize that this phenomenon is not associatedwith the replacement
of receptor subunits, as previously suggested. Long-term use of benzo-
diazepines acting as positive allosteric modulators of GABA action at
GABAA receptors in animals and humans has been associated with mo-
lecular modulations of these receptors and probably participate in themechanisms of tolerance characterized by a decreased ability of drugs
to exert their pharmacological effects (for review see Bateson, 2002;
Wafford, 2005). However, the molecular mechanisms that underlie tol-
erance and dependence are still unclear and rather complex (for review
see Bateson, 2002;Wafford, 2005). In the present study,we have shown
that two-day zolpidem treatment of CGCs expressing GABAA receptors
does not change the maximum number of benzodiazepine binding
sites or the expression of α1 mRNA. However, zolpidem treatment
could lead to declined GABAergic activity of the receptor. The exact
functional consequences of zolpidem-mediated reduction in allosteric
linkages between GABA and benzodiazepine binding sites at GABAA re-
ceptors should be determined by additional electrophysiological
studies.
Conclusion
These results demonstrate that two-day treatment of CGCs with
zolpidem (10 μM) did not induce changes either in the number of ben-
zodiazepine binding sites of GABAA receptors or in the expression of
GABAA receptor α1 subunit mRNA. As demonstrated by a decreased
ability of GABA to stimulate [3H]flunitrazepam binding, two-day expo-
sure of these cells to zolpidem caused functional uncoupling of GABA
and benzodiazepine binding sites at GABAA receptor complexes. If this
mechanism is responsible for the development of tolerance following
chronic administration of classic benzodiazepines, zolpidem treatment
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